Opinion of the Transparency Council – theophyllinum
At its meeting on 2 September 2024, the Transparency Council adopted opinion No. 144/2024 on the inclusion in reimbursement of medicines containing the active substance theophyllinum in the scope of indications for use or dosage or mode of administration different from those specified in the Summary of Product Characteristics, i.e. bradycardia in children under 18 years of age